OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
3886$0.2256

Town Health International Medical Group Ltd

Healthcare Facilities & ServicesVerified

Town Health International Medical Group Ltd has a market capitalization of HKD 1.48 billion and a price-to-earnings ratio of 102.71, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 0.49, suggesting that its market value is significantly lower than its book value, which may reflect market skepticism about its future earnings potential. The enterprise value to EBITDA ratio is 16.68, and the enterprise value to revenue ratio is 0.91, both of which are relatively low compared to industry norms, indicating a potentially undervalued company. In terms of profitability, the company's return on equity is 0.48%, and its return on assets is 0.36%, both of which are below the industry median for healthcare providers. This suggests that the company is not generating strong returns relative to its equity and asset base. The gross profit margin is 26.0%, and the operating margin is 5.5%, which are in line with the industry average but do not indicate exceptional performance. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility due to regional economic or regulatory changes. The company's total revenue for the latest period is HKD 1.79 billion, with a gross profit of HKD 464.15 million and an operating income of HKD 97.35 million. Looking ahead, the company's revenue is expected to grow modestly, with a projected increase of less than 5% in the next fiscal year. This growth is driven by expansion in existing markets and the introduction of new services. However, the company's net income is relatively low at HKD 14.38 million, which may limit its ability to reinvest in growth initiatives. The company faces several risk factors, including liquidity concerns due to negative net cash after subtracting total debt. The debt-to-equity ratio is 0.05, indicating a low level of leverage, but the current ratio of 3.64 suggests that the company has sufficient short-term assets to cover its liabilities. The risk of dilution is currently low, as the company has not issued additional shares recently, and there are no indications of a near-term need for capital raising. Recent filings and transcripts indicate that the company is focused on improving operational efficiency and expanding its service offerings. There are no major regulatory or legal issues currently affecting the company, and its financial position remains stable despite the low profitability.

30-day price · 3886(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyTown Health International Medical Group Ltd
Ticker3886.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Town Health International Medical Group Ltd provides healthcare services and operates in the biotechnology sector, generating revenue primarily through medical services and related operations.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Town Health International Medical Group Ltd has a market capitalization of HKD 1.48 billion and a price-to-earnings ratio of 102.71, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 0.49, suggesting that its market value is significantly lower than its book value, which may reflect market skepticism about its future earnings potential. The enterprise value to EBITDA ratio is 16.68, and the enterprise value to revenue ratio is 0.91, both of which are relatively low compared to industry norms, indicating a potentially undervalued company. In terms of profitability, the company's return on equity is 0.48%, and its return on assets is 0.36%, both of which are below the industry median for healthcare providers. This suggests that the company is not generating strong returns relative to its equity and asset base. The gross profit margin is 26.0%, and the operating margin is 5.5%, which are in line with the industry average but do not indicate exceptional performance. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility due to regional economic or regulatory changes. The company's total revenue for the latest period is HKD 1.79 billion, with a gross profit of HKD 464.15 million and an operating income of HKD 97.35 million. Looking ahead, the company's revenue is expected to grow modestly, with a projected increase of less than 5% in the next fiscal year. This growth is driven by expansion in existing markets and the introduction of new services. However, the company's net income is relatively low at HKD 14.38 million, which may limit its ability to reinvest in growth initiatives. The company faces several risk factors, including liquidity concerns due to negative net cash after subtracting total debt. The debt-to-equity ratio is 0.05, indicating a low level of leverage, but the current ratio of 3.64 suggests that the company has sufficient short-term assets to cover its liabilities. The risk of dilution is currently low, as the company has not issued additional shares recently, and there are no indications of a near-term need for capital raising. Recent filings and transcripts indicate that the company is focused on improving operational efficiency and expanding its service offerings. There are no major regulatory or legal issues currently affecting the company, and its financial position remains stable despite the low profitability.
Key takeaways
  • The company is trading at a high price-to-earnings ratio, suggesting market optimism despite low profitability.
  • Return on equity and return on assets are below industry medians, indicating subpar performance.
  • Revenue is concentrated in a single segment with no geographic diversification, increasing exposure to regional risks.
  • Liquidity is a concern due to negative net cash after debt, but the current ratio is strong.
  • Growth is expected to be modest, driven by market expansion and new services.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$1.79B
Gross profit$464.2M
Operating income$97.3M
Net income$14.4M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$3.95B
Total liabilities$957.1M
Total equity$3.00B
Cash & equivalents
Long-term debt$147.6M
Valuation
Market price$0.22
Market cap$1.48B
Enterprise value$1.62B
P/E102.7
Reported non-GAAP P/E
EV/Revenue0.9
EV/Op income16.7
EV/OCF
P/B0.5
P/Tangible book0.5
Tangible book$3.00B
Net cash-$147.6M
Current ratio3.6
Debt/Equity0.1
ROA0.4%
ROE0.5%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric3886Activity
Op margin5.5%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin0.8%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin26.0%28.8% medp25 28.8% · p75 28.8%bottom quartile
CapEx / revenue4.2% medp25 3.8% · p75 4.2%
Debt / equity5.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-24 15:55 UTCJob: da18a402